GOODTCELLS succeeds in attracting KRW 5 billion from Yuhan Corporation
GOODTCELLS, a biopharmaceutical venture specializing in immune disorder therapies, announced on the 23rd that the company succeeded in attracting a KRW 5 billion investment from Yuhan Corporation(CEO Jung-Hee Lee).
Yuhan Corporation will keep 6.25% of the company share by investing KRW 5 billion...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
